Payment overview · 2025
General Payments
$50,626.86
114 reported records · 8 companies
Healthcare provider profile · identity verified
Michael B Newnam, MD
Allopathic & Osteopathic Physicians|Family Medicine|Sleep Medicine · TULSA, OK · NPI 1851355812
Verified facts
What the public records show
CMS Open Payments records show Michael B Newnam, MD received $50,626.86 in general payments during 2025 across 114 reported records.
JAZZ PHARMACEUTICALS INC. accounted for 98.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Xywav.
JAZZ PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYREM as an associated drug or biological on 613 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xyrem by this doctor in 2024.
JAZZ PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYWAV as an associated drug or biological on 19511 records involving 5343 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xywav by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $49,742.21 | 98.2% | 86 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $226.88 | 0.5% | 11 | 2025 |
| ZOLL Respicardia, Inc. | Unresolved — no canonical attribution shown | $197.05 | 0.4% | 2 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $190.89 | 0.4% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $123.29 | 0.2% | 2 | 2025 |
| Fisher & Paykel Healthcare Inc | Unresolved — no canonical attribution shown | $93.37 | 0.2% | 4 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $27.38 | 0.1% | 1 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $25.79 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $42,140.00 | 14 |
| Travel and Lodging | $5,428.58 | 24 |
| Food and Beverage | $2,878.30 | 74 |
| Education | $179.98 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $49,742.21 | 86 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $226.88 | 11 | 2025 |
Source payment records
|
|||||
| remede System Normalized: remede system |
Device | ZOLL Respicardia, Inc. | $197.05 | 2 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $190.89 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $123.29 | 2 | 2025 |
Source payment records
|
|||||
| FISHER & PAYKEL HEALTHCARE Normalized: fisher paykel healthcare |
Device | Fisher & Paykel Healthcare Inc | $93.37 | 4 | 2025 |
Source payment records
|
|||||
| DreamWear Normalized: dreamwear |
Device | Philips North America LLC | $27.38 | 1 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $25.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| XYWAV xywav |
2025 | Xywav | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | XYREM open payments reported associated product |
CMS Open Payments — General Payments 613 supporting records · 589 recipient NPIs · example record 1234298066 |
Xyrem · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| JAZZ PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | XYWAV open payments reported associated product |
CMS Open Payments — General Payments 19511 supporting records · 5343 recipient NPIs · example record 1234297700 |
Xywav · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Zolpidem Tartrate | Zolpidem Tartrate | 451 | 347 |
| Quetiapine Fumarate | Quetiapine Fumarate | 162 | 43 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 111 | 14 |
| Clonazepam | Clonazepam | 108 | 15 |
| Belsomra | Suvorexant | 78 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 64 | 18 |
| Armodafinil | Armodafinil | 60 | 12 |
| Eszopiclone | Eszopiclone | 59 | 21 |
| Trazodone Hcl | Trazodone Hcl | 53 | 17 |
| Modafinil | Modafinil | 51 | 11 |
| Gabapentin | Gabapentin | 47 | suppressed |
| Sunosi | Solriamfetol Hcl | 36 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 35 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Xyrem | Sodium Oxybate | 12 | suppressed |
| Quviviq | Daridorexant Hcl | 11 | suppressed |
| Xywav | Sodium,calcium,mag,pot Oxybate | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $50,626.86 · 114 records | JAZZ PHARMACEUTICALS INC. | DreamWear, FISHER & PAYKEL HEALTHCARE, INSPIRE, LUMRYZ, WAKIX, XYWAV, ZEPBOUND, remede System | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Xywav play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with JAZZ PHARMACEUTICALS INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error